Syndexa Pharmaceuticals
Watertown
About Syndexa Pharmaceuticals
Syndexa Pharmaceuticals Corp., a Watertown, MA-based biopharmaceutical company developing drugs to treat metabolic diseases. Founded by scientists from Harvard University, and led by President and CEO Teo Uysal, Syndexa is dedicated to the discovery and development of a new generation of small-molecule drugs targeting novel mechanisms for the treatment and prevention of diseases of endoplasmic reticulum (ER) dysfunction which include inflammatory and metabolic diseases and disorders, cardiovascular diseases and neurodegenerative diseases. The company has raised $24.8m of equity capital to date.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $23.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2012)
- Website: syndexa.com
- Phone: 617-607-7283
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Canonical: https://fsome.com/organization/syndexa-pharmaceuticals-1500767 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.